Citigroup’s Evoke Pharma EVOK Stock Holding History

Citigroup’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4	Closed	-$20	–	5871
2024 Q3	$20	Buy	+4	New	+$21	﹤0.01%	5595
2022 Q3	–	Sell	-68	Closed	-$3K	–	5970
2022 Q2	$3K	Buy	+68	New	+$3.24K	﹤0.01%	5770
2021 Q3	–	Sell	-3	Closed	-$1K	–	5909
2021 Q2	$1K	Hold	3	–	–	﹤0.01%	6030
2021 Q1	$1K	Hold	3	–	–	﹤0.01%	6097
2020 Q4	$1K	Hold	3	–	–	﹤0.01%	7282
2020 Q3	$2K	Hold	3	–	–	﹤0.01%	7290
2020 Q2	$2K	Hold	3	–	–	﹤0.01%	7403
2020 Q1	$1K	Hold	3	–	–	﹤0.01%	7494
2019 Q4	$1K	Hold	3	–	–	﹤0.01%	7590
2019 Q3	$0	Hold	3	–	–	﹤0.01%	7718
2019 Q2	$0	Hold	3	–	–	﹤0.01%	7767
2019 Q1	$1K	Hold	3	–	–	﹤0.01%	7574
2018 Q4	$1K	Hold	3	–	–	﹤0.01%	7568
2018 Q3	$1K	Hold	3	–	–	﹤0.01%	7656
2018 Q2	$1K	Hold	3	–	–	﹤0.01%	7520
2018 Q1	$1K	Hold	3	–	–	﹤0.01%	7435
2017 Q4	$1K	Hold	3	–	–	﹤0.01%	7468
2017 Q3	$2K	Buy	+3	New	+$1.16K	﹤0.01%	7015
2016 Q2	–	Hold	0	–	–	–	7161
2016 Q1	–	Hold	0	–	–	–	7521
2015 Q2	–	Hold	0	–	–	–	7581
2015 Q1	–	Hold	0	–	–	–	7251
2014 Q2	–	Sell	-14	Closed	-$17K	–	7164
2014 Q1	$17K	Buy	+14	New	+$20K	﹤0.01%	6115

Other funds holding EVOK

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's EVOK Position: Q4 2024 in Review

Citigroup sold out of Evoke Pharma (EVOK) in Q4 2024, closing a stake of 4 shares — an estimated $20 sold.

Citigroup first reported a position in EVOK in Q1 2014 and held it in 19 quarters. The position peaked at $17K in Q1 2014. 8 funds tracked by Wall St. Rank hold EVOK as of Q4 2024.

Citigroup reported no remaining Evoke Pharma position as of Q4 2024 after selling out during the quarter.
Citigroup sold 4 Evoke Pharma shares in Q4 2024, an estimated $20.
Citigroup first reported a position in Evoke Pharma in Q1 2014 and held it in 19 quarters.
Citigroup's Evoke Pharma position peaked at $17K in Q1 2014.
8 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2024.

Based on Citigroup's 13F filing for Q4 2024, filed 12 Feb 2025.